Trial
NCT05280158
High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, Los Angeles
Collaborators
ModernaTX, Inc.
Condition
Lung Transplant Recipient
Intervention
mRNA-1273 (Moderna COVID-19 vaccine)
Why stopped
Moderna Bivalent COVID-19 Vaccine became available to the public in Sept 2022.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-26